CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES >

2022 , Vol. 40 >Issue 5: 661 - 667

DOI: https://doi.org/10.12140/j.issn.1000-7423.2022.05.015

REVIEWS

Research advances of multi-epitope vaccine candidates against toxoplasmosis

  • LI Run-hua ,
  • YIN Guo-rong
Expand
  • 1. Department of Biology, Taiyuan Normal University, Jinzhong 030619, China
    2. Institute of Medical Parasitology, Shanxi Medical University, Taiyuan 030001, China

Received date: 2022-02-01

  Revised date: 2022-03-24

  Online published: 2022-10-10

Supported by

National Natural Science Foundation of China(81071374)

Fold

Abstract

Toxoplasma gondii infects almost all warm-blooded animals causing toxoplasmosis in humans and animals. Despite the significant progress in the recent efforts toward developing an effective vaccine against toxoplasmosis, no human vaccines are available to prevent this disease. However, vaccines based on a single or a few antigen candidates was only able to elicit partial protective immunity against T. gondii infection. Therefore, developing a polyvalent vaccine consisting of antigens from all stages of the parasite life cycle, including tachyzoites, bradyzoites, and sporozoites, is likely to be essential for sterile immunity. The combination of multi-epitopes from antigens of different stages of the parasite life cycle has become an promising strategy for building a potent, safe, and effective vaccine. Epitope-based vaccines have gained attention as novel vaccine candidates due to their ability of inducing protective immune responses. In this review, we have summarized the immunological basis, design, and construction strategy of epitope vaccines. We have reviewed the latest research advances of T. gondii epitope vaccines, and the application prospect of epitope vaccines as a new vaccine development and evaluation strategy.

Key words： Toxoplasmosis; B- and T-cell epitopes; Multi-epitope vaccine; Antigenic epitope

Cite this article

LI Run-hua , YIN Guo-rong . Research advances of multi-epitope vaccine candidates against toxoplasmosis[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2022 , 40(5) : 661 -667 . DOI: 10.12140/j.issn.1000-7423.2022.05.015

References

[1] Dubey JP. History of the discovery of the life cycle of Toxoplasma gondii[J]. Int J Parasitol, 2009, 39(8): 877-882.
[2] Barros M,, Teixeira D,, Vilanova M, et al. Vaccines in congenital toxoplasmosis: advances and perspectives[J]. Front Immunol, 2021, 11: 621997.
[3] Csep A,, Vaida LL,, Negrut?iu BM, et al. Research on demographic, clinical and paraclinical aspects in pregnant women infected with Toxoplasma gondii[J]. Exp Ther Med, 2022, 23(2): 123.
[4] Hajissa K,, Zakaria R,, Suppian R, et al. An evaluation of a recombinant multiepitope based antigen for detection of Toxoplasma gondii specific antibodies[J]. BMC Infect Dis, 2017, 17(1): 807.
[5] Lakhrif Z,, Moreau A,, Hérault B, et al. Targeted delivery of Toxoplasma gondii antigens to dendritic cells promote immunogenicity and protective efficiency against toxoplasmosis[J]. Front Immunol, 2018, 9: 317.
[6] Zhang ZC,, Li YH,, Wang MY, et al. Immune protection of rhoptry protein 21 (ROP21) of Toxoplasma gondii as a DNA vaccine against toxoplasmosis[J]. Front Microbiol, 2018, 9: 909.
[7] Liu Y,, Cao AP,, Li YW, et al. Immunization with a DNA vaccine encoding Toxoplasma gondii Superoxide dismutase (TgSOD) induces partial immune protection against acute toxoplasmosis in BALB/c mice[J]. BMC Infect Dis, 2017, 17(1): 403.
[8] Li YW,, Zhou HY. Moving towards improved vaccines for Toxoplasma gondii[J]. Expert Opin Biol Ther, 2018, 18(3): 273-280.
[9] Chu KB,, Quan FS. Advances in Toxoplasma gondii vaccines: current strategies and challenges for vaccine development[J]. Vaccines (Basel), 2021, 9(5): 413.
[10] Hiszczyńska-Sawicka E,, Gatkowska JM,, Grzybowski MM, et al. Veterinary vaccines against toxoplasmosis[J]. Parasitology, 2014, 141(11): 1365-1378.
[11] Zhou CX,, Zhou DH,, Liu GX, et al. Transcriptomic analysis of porcine PBMCs infected with Toxoplasma gondii RH strain[J]. Acta Trop, 2016, 154: 82-88.
[12] Cong H,, Yuan Q,, Zhao QL, et al. Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice[J]. Parasit Vectors, 2014, 7: 145.
[13] Foroutan M,, Ghaffarifar F. Calcium-dependent protein kinases are potential targets for Toxoplasma gondii vaccine[J]. Clin Exp Vaccine Res, 2018, 7(1): 24-36.
[14] Cong H,, Gu QM,, Yin HE, et al. Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protect mice against Toxoplasma gondii[J]. Vaccine, 2008, 26(31): 3913-3921.
[15] Cheong FW,, Fong MY,, Lau YL. Identification and characterization of epitopes on Plasmodium knowlesi merozoite surface protein-142 (MSP-142) using synthetic peptide library and phage display library[J]. Acta Trop, 2016, 154: 89-94.
[16] Stoloff GA,, Caparros-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes[J]. Eur J Immunol, 2007, 37(9): 2441-2449.
[17] Alonso-Padilla J,, Lafuente EM,, Reche PA. Computer-aided design of an epitope-based vaccine against Epstein-Barr virus[J]. J Immunol Res, 2017, 2017: 9363750.
[18] Thompson CP,, Lourenço J,, Walters AA, et al. A naturally protective epitope of limited variability as an influenza vaccine target[J]. Nat Commun, 2018, 9(1): 3859.
[19] Huang SY,, Jensen MR,, Rosenberg CA, et al. In silico and in vivo analysis of Toxoplasma gondii epitopes by correlating survival data with peptide-MHC-I binding affinities[J]. Int J Infect Dis, 2016, 48: 14-19.
[20] Palatnik-de-Sousa CB,, Soares IS,, Rosa DS. Editorial: epitope discovery and synthetic vaccine design[J]. Front Immunol, 2018, 9: 826.
[21] Ma FS,, Zhang L,, Wang Y, et al. Advance on prediction methods of B-cell antigen epitope[J]. China Animal Husb Vet Med, 2016, 43(1): 63-67. (in Chinese)
[21] ( 马凡舒,, 张蕾,, 王洋, 等. B细胞抗原表位预测方法的研究进展[J]. 中国畜牧兽医, 2016, 43(1): 63-67.)
[22] Hajissa K,, Zakaria R,, Suppian R, et al. Epitope-based vaccine as a universal vaccination strategy against Toxoplasma gondii infection: a mini-review[J]. J Adv Vet Anim Res, 2019, 6(2): 174-182.
[23] Pulendran B,, Ahmed R. Immunological mechanisms of vaccination[J]. Nat Immunol, 2011, 12(6): 509-517.
[24] Bastos LM,, Macêdo AG Jr,, Silva MV, et al. Toxoplasma gondii-derived synthetic peptides containing B-and T-cell epitopes from GRA2 protein are able to enhance mice survival in a model of experimental toxoplasmosis[J]. Front Cell Infect Microbiol, 2016, 6: 59.
[25] Hajissa K,, Zakaria R,, Suppian R, et al. Immunogenicity of multiepitope vaccine candidate against Toxoplasma gondii infection in BALB/c mice[J]. Iran J Parasitol, 2018, 13(2): 215-224.
[26] Zhang TE,, Yin LT,, Li RH, et al. Protective immunity induced by peptides of AMA1, RON2 and RON4 containing T-and B-cell epitopes via an intranasal route against toxoplasmosis in mice[J]. Parasit Vectors, 2015, 8: 15.
[27] Dodangeh S,, Fasihi-Ramandi M,, Daryani A, et al. Protective efficacy by a novel multi-epitope vaccine, including MIC3, ROP8, and SAG1, against acute Toxoplasma gondii infection in BALB/c mice[J]. Microb Pathog, 2021, 153: 104764.
[28] Shi JD,, Zhang J,, Li SJ, et al. Epitope-based vaccine target screening against highly pathogenic MERS-CoV: an in silico approach applied to emerging infectious diseases[J]. PLoS One, 2015, 10(12): e0144475.
[29] Patronov A,, Doytchinova I. T-cell epitope vaccine design by immunoinformatics[J]. Open Biol, 2013, 3(1): 120139.
[30] Correia BE,, Bates JT,, Loomis RJ, et al. Proof of principle for epitope-focused vaccine design[J]. Nature, 2014, 507(7491): 201-206.
[31] Zhou J,, Wang L,, Lu G, et al. Epitope analysis and protection by a ROP19 DNA vaccine against Toxoplasma gondii[J]. Parasite, 2016, 23: 17.
[32] Lu G,, Wang L,, Zhou AH, et al. Epitope analysis, expression and protection of SAG5A vaccine against Toxoplasma gondii[J]. Acta Trop, 2015, 146: 66-72.
[33] Mahajan B,, Berzofsky JA,, Boykins RA, et al. Multiple antigen peptide vaccines against Plasmodium falciparum malaria[J]. Infect Immun, 2010, 78(11): 4613-4624.
[34] Khan AM,, Miotto O,, Heiny AT, et al. A systematic bioinformatics approach for selection of epitope-based vaccine targets[J]. Cell Immunol, 2006, 244(2): 141-147.
[35] Moise L,, Gutierrez A,, Kibria F, et al. iVAX: an integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines[J]. Hum Vaccin Immunother, 2015, 11(9): 2312-2321.
[36] de Groot AS,, Moise L,, Terry F, et al. Better epitope discovery, precision immune engineering, and accelerated vaccine design using immunoinformatics tools[J]. Front Immunol, 2020, 11: 442.
[37] Zhang NZ,, Chen J,, Wang M, et al. Vaccines against Toxoplasma gondii: new developments and perspectives[J]. Expert Rev Vaccines, 2013, 12(11): 1287-1299.
[38] Muñoz-Medina JE,, Sánchez-Vallejo CJ,, Méndez-Tenorio A, et al. In silico identification of highly conserved epitopes of influenza A H1N1, H2N2, H3N2, and H5N1 with diagnostic and vaccination potential[J]. Biomed Res Int, 2015, 2015: 813047.
[39] Sahay B,, Nguyen CQ,, Yamamoto JK. Conserved HIV epitopes for an effective HIV vaccine[J]. J Clin Cell Immunol, 2017, 8(4): 518.
[40] Comber JD,, Karabudak A,, Shetty V, et al. MHC class Ⅰ presented T cell epitopes as potential antigens for therapeutic vaccine against HBV chronic infection[J]. Hepat Res Treat, 2014, 2014: 860562.
[41] Ramana J,, Mehla K. Immunoinformatics and epitope prediction[J]. Methods Mol Biol, 2020, 2131: 155-171.
[42] Forouharmehr A. Engineering an efficient poly-epitope vaccine against Toxoplasma gondii infection: a computational vaccinology study[J]. Microb Pathog, 2021, 152: 104646.
[43] Parvizpour S,, Pourseif MM,, Razmara J, et al. Epitope-based vaccine design: a comprehensive overview of bioinformatics approaches[J]. Drug Discov Today, 2020, 25(6): 1034-1042.
[44] Ip PP,, Nijman HW,, Daemen T. Epitope prediction assays combined with validation assays strongly narrows down putative cytotoxic T lymphocyte epitopes[J]. Vaccines (Basel), 2015, 3(2): 203-220.
[45] Agallou M,, Athanasiou E,, Koutsoni O, et al. Experimental validation of multi-epitope peptides including promising MHC class Ⅰ- and Ⅱ-restricted epitopes of four known Leishmania infantum proteins[J]. Front Immunol, 2014, 5: 268.
[46] Saha S,, Raghava GPS. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network[J]. Proteins, 2006, 65(1): 40-48.
[47] Javadi Mamaghani A,, Fathollahi A,, Spotin A, et al. Candidate antigenic epitopes for vaccination and diagnosis strategies of Toxoplasma gondii infection: a review[J]. Microb Pathog, 2019, 137: 103788.
[48] Sette A,, Fikes J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery[J]. Curr Opin Immunol, 2003, 15(4): 461-470.
[49] Xu QQ,, Ma XJ,, Wang FK, et al. Design and construction of a chimeric multi-epitope gene as an epitope-vaccine strategy against ALV-J[J]. Protein Expr Purif, 2015, 106: 18-24.
[50] Parmiani G,, Russo V,, Maccalli C, et al. Peptide-based vaccines for cancer therapy[J]. Hum Vaccin Immunother, 2014, 10(11): 3175-3178.
[51] Li MD,, Kaminskas LM,, Marasini N. Recent advances in nano/microparticle-based oral vaccines[J]. J Pharm Investig, 2021, 51(4): 425-438.
[52] El Bissati K,, Zhou Y,, Dasgupta D, et al. Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice[J]. Vaccine, 2014, 32(26): 3243-3248.
[53] Bissati KE,, Chentoufi AA,, Krishack PA, et al. Adjuvanted multi-epitope vaccines protect HLA-A*11: 01 transgenic mice against Toxoplasma gondii[J]. JCI Insight, 2016, 1(15): e85955.
[54] Wang YH,, Wang M,, Wang GX, et al. Increased survival time in mice vaccinated with a branched lysine multiple antigenic peptide containing B- and T-cell epitopes from T. gondii antigens[J]. Vaccine, 2011, 29(47): 8619-8623.
[55] Cao AP,, Liu Y,, Wang JJ, et al. Toxoplasma gondii: vaccination with a DNA vaccine encoding T- and B-cell epitopes of SAG1, GRA2, GRA7 and ROP16 elicits protection against acute toxoplasmosis in mice[J]. Vaccine, 2015, 33(48): 6757-6762.
[56] Blanchard N,, Gonzalez F,, Schaeffer M, et al. Immunodominant, protective response to the parasite Toxoplasma gondii requires antigen processing in the endoplasmic reticulum[J]. Nat Immunol, 2008, 9(8): 937-944.
[57] Sun XM,, Zou J,, Elashram Saeed AA, et al. DNA vaccination with a gene encoding Toxoplasma gondii GRA6 induces partially protection in BALB/c mice with an H-2Ld allele[J]. Parasit Vectors, 2011, 4: 213.
[58] Foroutan M,, Ghaffarifar F,, Sharifi Z, et al. Vaccination with a novel multi-epitope ROP8 DNA vaccine against acute Toxoplasma gondii infection induces strong B and T cell responses in mice[J]. Comp Immunol Microbiol Infect Dis, 2020, 69: 101413.
[59] Foroutan M,, Barati M,, Ghaffarifar F. Enhancing immune responses by a novel multi-epitope ROP8 DNA vaccine plus interleukin-12 plasmid as a genetic adjuvant against acute Toxoplasma gondii infection in BALB/c mice[J]. Microb Pathog, 2020, 147: 104435.
[60] Khodadadi M,, Ghaffarifar F,, Dalimi A, et al. Immunogenicity of in-silico designed multi-epitope DNA vaccine encoding SAG1, SAG3 and SAG5 of Toxoplasma gondii adjuvanted with CpG-ODN against acute toxoplasmosis in BALB/c mice[J]. Acta Trop, 2021, 216: 105836.
[61] Guo JJ,, Zhou AH Sun XH, et al. Immunogenicity of a virus-like-particle vaccine containing multiple antigenic epitopes of Toxoplasma gondii against acute and chronic toxoplasmosis in mice[J]. Front Immunol, 2019, 10: 592.
Options
Outlines

/

〈 〉